Home LiteratureArticle Details
PMID: 19005564 Published · ppublish English Journal Article

Epidemiology of doublet/multiplet mutations in lung cancers: evidence that a subset arises by chronocoordinate events.

PloS one ·Vol. 3 ·No. 11 ·2008-00-00 ·Pages e3714

Chen Z, Feng J, Buzin CH, Sommer SS

Abstract

Evidence strongly suggests that spontaneous doublet mutations in normal mouse tissues generally arise from chronocoordinate events. These chronocoordinate mutations sometimes reflect "mutation showers", which are multiple chronocoordinate mutations spanning many kilobases. However, little is known about mutagenesis of doublet and multiplet mutations (domuplets) in human cancer. Lung cancer accounts for about 25% of all cancer deaths. Herein, we analyze the epidemiology of domuplets in the EGFR and TP53 genes in lung cancer. The EGFR gene is an oncogene in which doublets are generally driver plus driver mutations, while the TP53 gene is a tumor suppressor gene with a more typical situation in which doublets derive from a driver and passenger mutation. EGFR mutations identified by sequencing were collected from 66 published papers and our updated EGFR mutation database (www.egfr.org). TP53 mutations were collected from IARC version 12 (www-p53.iarc.fr). For EGFR and TP53 doublets, no clearly significant differences in race, ethnicity, gender and smoking status were observed. Doublets in the EGFR and TP53 genes in human lung cancer are elevated about eight- and three-fold, respectively, relative to spontaneous doublets in mouse (6% and 2.3% versus 0.7%). Although no one characteristic is definitive, the aggregate properties of doublet and multiplet mutations in lung cancer are consistent with a subset derived from chronocoordinate events in the EGFR gene: i) the eight frameshift doublets (present in 0.5% of all patients with EGFR mutations) are clustered and produce a net in-frame change; ii) about 32% of doublets are very closely spaced (< or =30 nt); and iii) multiplets contain two or more closely spaced mutations. TP53 mutations in lung cancer are very closely spaced (< or =30 nt) in 33% of doublets, and multiplets generally contain two or more very closely spaced mutations. Work in model systems is necessary to confirm the significance of chronocoordinate events in lung and other cancers.

MeSH Terms
Aged Animals DNA Mutational Analysis Female Frameshift Mutation Genes, erbB-1 Genes, p53 Humans Lung Neoplasms/genetics Male Mice Middle Aged Mutation Risk Factors
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Chen Zhenbin
Department of Molecular Genetics, City of Hope National Medical Center, Duarte, CA, USA.
Feng Jinong
Buzin Carolyn H
Sommer Steve S
References (30)
30 references, click to expand
  1. EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: one-third of doublets occur at five pairs of amino acids.
    Oncogene. 2008 Jul 17;27(31):4336-43 PMID: 18372921
  2. Spontaneous tandem-base mutations (TBM) show dramatic tissue, age, pattern and spectrum specificity.
    Mutat Res. 2003 Jan 10;534(1-2):173-86 PMID: 12504766
  3. p53 as a mutagen test in breast cancer.
    Environ Mol Mutagen. 2002;39(2-3):216-27 PMID: 11921192
  4. Multiple mutations and cancer.
    Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):776-81 PMID: 12552134
  5. Role in tumorigenesis of silent mutations in the TP53 gene.
    Mutat Res. 2000 Dec 20;457(1-2):93-104 PMID: 11106801
  6. Searching for the 1 in 2,400,000: a review of dystrophin gene point mutations.
    Hum Mutat. 1994;4(1):1-11 PMID: 7951253
  7. Mutator phenotype in cancer: timing and perspectives.
    Environ Mol Mutagen. 2005 Mar-Apr;45(2-3):206-13 PMID: 15672382
  8. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
    PLoS Med. 2005 Mar;2(3):e73 PMID: 15737014
  9. Evidence that proximal multiple mutations in Big Blue transgenic mice are dependent events.
    Mutat Res. 2000 Sep 18;452(2):219-29 PMID: 11024481
  10. Mutagen test.
    Nature. 1990 Jul 5;346(6279):22-3 PMID: 2142254
  11. Human germline mutation in the factor IX gene.
    Mutat Res. 2001 Nov 1;487(1-2):1-17 PMID: 11595404
  12. The consensus coding sequences of human breast and colorectal cancers.
    Science. 2006 Oct 13;314(5797):268-74 PMID: 16959974
  13. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features.
    Clin Cancer Res. 2006 Mar 1;12(5):1647-53 PMID: 16533793
  14. The size distributions of proteins, mRNA, and nuclear RNA.
    J Mol Evol. 1980 Mar;15(1):37-57 PMID: 6154144
  15. Selection, the mutation rate and cancer: ensuring that the tail does not wag the dog.
    Nat Med. 1999 Jan;5(1):11-2 PMID: 9883827
  16. Two genetic hits (more or less) to cancer.
    Nat Rev Cancer. 2001 Nov;1(2):157-62 PMID: 11905807
  17. Tandem-base mutations occur in mouse liver and adipose tissue preferentially as G:C to T:A transversions and accumulate with age.
    Environ Mol Mutagen. 1999;33(4):320-4 PMID: 10398380
  18. Evidence for mutation showers.
    Proc Natl Acad Sci U S A. 2007 May 15;104(20):8403-8 PMID: 17485671
  19. Spontaneous multiple mutations show both proximal spacing consistent with chronocoordinate events and alterations with p53-deficiency.
    Mutat Res. 2004 Oct 4;554(1-2):223-40 PMID: 15450421
  20. Silent and multiple mutations in p53 and the question of the hypermutability of tumors.
    Carcinogenesis. 1997 Aug;18(8):1445-52 PMID: 9276614
  21. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
    N Engl J Med. 2005 Feb 24;352(8):786-92 PMID: 15728811
  22. EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification.
    Cancer Sci. 2006 Aug;97(8):753-9 PMID: 16863509
  23. Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature.
    Hum Mutat. 2007 Aug;28(8):760-70 PMID: 17429853
  24. Spontaneous microdeletions and microinsertions in a transgenic mouse mutation detection system: analysis of age, tissue, and sequence specificity.
    Environ Mol Mutagen. 2001;37(4):311-23 PMID: 11424181
  25. Too many mutants with multiple mutations.
    Crit Rev Biochem Mol Biol. 2007 Jul-Aug;42(4):247-58 PMID: 17687667
  26. The mutation rate and cancer.
    Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14800-3 PMID: 8962135
  27. Reported in vivo splice-site mutations in the factor IX gene: severity of splicing defects and a hypothesis for predicting deleterious splice donor mutations.
    Hum Mutat. 1999;13(3):221-31 PMID: 10090477
  28. A mutator phenotype in cancer.
    Cancer Res. 2001 Apr 15;61(8):3230-9 PMID: 11309271
  29. Clusters of mutations from transient hypermutability.
    Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12849-54 PMID: 16118275
  30. The hallmarks of cancer.
    Cell. 2000 Jan 7;100(1):57-70 PMID: 10647931
Article Info
Journal
PloS one
Abbr.
PLoS One
ISSN
1932-6203
Published
2008-00-00
Epub
2008-00-13
Pages
e3714
Language
English
Region
United States
NLM ID
101285081
PMCID
PMC2579325
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com